Alpha-synuclein protein clumps — the toxic aggregates related to nerve damage in Parkinson’s disease — vary, including in size, and small fragments appear to drive cellular toxicity compared with larger fragments, a study shows. Its findings were confirmed in post-mortem examinations of brain tissue from Parkinson’s patients, showing smaller clumps…
Fifty new genes that modified signs of Parkinson’s disease in a fruit fly model have been discovered using a multidisciplinary approach involving genomics, computational tools, and patient sample analysis, a study has reported. Some gene candidates worsened Parkinson’s signs while others conferred neuroprotection, “underscoring their therapeutic potential,” the researchers…
A Phase 1/2a clinical trial testing the ability of AMDX-2011P to safely detect abnormal protein deposits in the retina of adults with Parkinson’s disease and amyotrophic lateral sclerosis (ALS), possibly allowing earlier diagnosis and easier patient monitoring, has dosed its first participants. These proteins comprise alpha-synuclein in Parkinson’s…
Clumps of alpha-synuclein protein, which build to toxic levels in the brain and spinal cord of Parkinson’s disease patients, spread via a cellular waste-ejection process, according to a study in mice. These clumps, which failed to be broken down in lysosomes, the cells’ recycling centers, are released by nerve…
Gain Therapeutics’ GT-02287, an oral candidate therapy for Parkinson’s disease, led to dose-dependent improvements in the health of nerve cells and fine motor skills in mice. These findings, presented recently as a poster at the International Congress of Parkinson’s Disease and Movement Disorders 2022 in Madrid, add to…
Using a newly created probe and non-invasive PET scans, researchers were able to visualize sites of alpha-synuclein protein clumps — associated with nerve damage in Parkinson’s disease — in the brains of living patients, scientists reported. This method may help in diagnosing conditions related to alpha-synuclein clumping, referred to…
Screening a large database with machine learning tools helped scientists identify approved medicines for other diseases that reduced the risk of developing Parkinson’s, a study reported. According to researchers, these potential Parkinson’s disease therapies “deserve to be confirmed” in larger studies. “Drug repurposing or repositioning is the application of…
In-home, non-contact sensors that can identify changes in movement and behaviors may allow age-related diseases, including Parkinson’s, to be detected early, a study reports. By using machine learning tools, the study shows how outcomes such as fall risk, frailty, and cognitive abilities may be assessed in a home setting.
Mirapex (pramipexole) improved the quality of life for people with Parkinson’s disease compared to a placebo, according to a pooled analysis of several clinical trials. Quality of life improvements were seen regardless of disease stage, duration of treatment, or quality of life assessments before treatment. This analysis provided new…
Older age at disease onset is associated with greater motor and nonmotor impairment in people with idiopathic Parkinson’s disease, according to a study by scientists in Luxembourg. Nonmotor symptoms such as urinary incontinence and apathy in those diagnosed at older ages were found to be mainly driven by the natural…
Get regular updates to your inbox.
